TARRYTOWN, N.Y., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. Chief Executive Officer Mark R. Baker will present at two upcoming investor conferences in New York City:
-
Brean Murray, Carret & Co. 2011 Life Sciences Summit beginning at 8:00 a.m. Eastern Time on Monday, November 14
- 8th Annual Lazard Capital Markets Healthcare Conference at 8:30 a.m. Eastern Time on Tuesday, November 15
Mr. Baker's presentation to the Lazard Capital Markets Healthcare Conference will be webcast live and will be archived for 30 days on the Events page of Progenics' website. The Brean Murray, Carret Life Sciences Summit will not include webcast presentations.
Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) develops innovative therapeutics for patients suffering from cancer and related conditions. Its pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 1 clinical testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics' first commercial product, RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection, is a first-in-class treatment for opioid-induced constipation. It is approved in over 50 countries for patients with advanced illness and licensed to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. is developing the subcutaneous formulation. A U.S. application for approval of RELISTOR to treat OIC in patients with chronic, non-cancer pain is pending and a phase 3 clinical trial of an oral formulation of methylnaltrexone in this patient population completed enrollment in mid-2011.
Additional information concerning Progenics and its business may be available in press releases or other announcements and public filings made after this release.
Progenics' logo is available at www.globenewswire.com/newsroom/prs/?pkgid=9678.
(PGNX-G)
Editors Note:
For more information, please visit www.progenics.com.